

# Bryan Oronsky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4282448/publications.pdf>

Version: 2024-02-01

89  
papers

2,612  
citations

257357

24  
h-index

214721

47  
g-index

89  
all docs

89  
docs citations

89  
times ranked

3420  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. <i>Neoplasia</i> , 2017, 19, 991-1002.	2.3	474
2	A Review of Persistent Post-COVID Syndrome (PPCS). <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 66-74.	2.9	219
3	What's New in SCLC? A Review. <i>Neoplasia</i> , 2017, 19, 842-847.	2.3	135
4	A brief review of the management of platinum-resistantâ€“platinum-refractory ovarian cancer. <i>Medical Oncology</i> , 2017, 34, 103.	1.2	125
5	Going viral: a review of replication-selective oncolytic adenoviruses. <i>Oncotarget</i> , 2015, 6, 19976-19989.	0.8	110
6	NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. <i>Redox Biology</i> , 2015, 6, 1-8.	3.9	98
7	Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials. <i>Cancer Research</i> , 2012, 72, 2600-2608.	0.4	90
8	Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 1133-1142.	5.1	76
9	Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 895-907.	1.1	70
10	Follow the ATP: Tumor Energy Production: A Perspective. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 1187-1198.	0.9	64
11	A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis. <i>Translational Oncology</i> , 2018, 11, 771-778.	1.7	63
12	Just eat it: A review of CD47 and SIRP-Î± antagonism. <i>Seminars in Oncology</i> , 2020, 47, 117-124.	0.8	50
13	RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 109-119.	1.9	45
14	Preclinical Evaluation of the Metabolism and Disposition of RRx-001, a Novel Investigative Anticancer Agent. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1810-1816.	1.7	44
15	Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. <i>Oncotarget</i> , 2015, 6, 43172-43181.	0.8	43
16	Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 1121-1127.	0.9	39
17	Rewriting the Epigenetic Code for Tumor Resensitization: A Review. <i>Translational Oncology</i> , 2014, 7, 626-631.	1.7	37
18	RRx-001, A novel dinitroazetidine radiosensitizer. <i>Investigational New Drugs</i> , 2016, 34, 371-377.	1.2	37

#	ARTICLE	IF	CITATIONS
19	REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3427-3433.	1.1	37
20	Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001. <i>Oncotarget</i> , 2015, 6, 21547-21556.	0.8	34
21	The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. <i>Clinical Epigenetics</i> , 2017, 9, 4.	1.8	33
22	Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial. <i>Translational Oncology</i> , 2016, 9, 108-113.	1.7	28
23	The Capacity of Red Blood Cells to Reduce Nitrite Determines Nitric Oxide Generation under Hypoxic Conditions. <i>PLoS ONE</i> , 2014, 9, e101626.	1.1	28
24	The Implications of Hyponitroxia in Cancer. <i>Translational Oncology</i> , 2014, 7, 167-173.	1.7	25
25	Navigating the “No Man’s Land” of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review. <i>Neoplasia</i> , 2018, 20, 92-98.	2.3	24
26	Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man: PFS2: A Measure of Therapeutic Action-At-A-Distance. <i>Neoplasia</i> , 2015, 17, 716-722.	2.3	21
27	RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors. <i>Clinical Epigenetics</i> , 2016, 8, 53.	1.8	20
28	RRx-001 protects against cisplatin-induced toxicities. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1671-1677.	1.2	18
29	Development of methods for the bioanalysis of RRx-001 and metabolites. <i>Bioanalysis</i> , 2014, 6, 947-956.	0.6	17
30	Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells. <i>Oncotarget</i> , 2018, 9, 23439-23442.	0.8	17
31	Nucleocapsid as a next-generation COVID-19 vaccine candidate. <i>International Journal of Infectious Diseases</i> , 2022, 122, 529-530.	1.5	17
32	Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7261-7271.	2.9	16
33	Rockets, radiosensitizers, and RRx-001: an origin story part I. <i>Discovery Medicine</i> , 2016, 21, 173-80.	0.5	16
34	RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells. <i>Discovery Medicine</i> , 2016, 21, 251-65.	0.5	16
35	From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. <i>Malaria Journal</i> , 2015, 14, 218.	0.8	15
36	The War on Cancer: A Military Perspective. <i>Frontiers in Oncology</i> , 2015, 4, 387.	1.3	15

#	ARTICLE	IF	CITATIONS
37	Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock. <i>Asian Journal of Transfusion Science</i> , 2015, 9, 55.	0.1	15
38	A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?. <i>Medical Oncology</i> , 2016, 33, 63.	1.2	15
39	Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. <i>Case Reports in Oncology</i> , 2016, 9, 164-170.	0.3	15
40	The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent. <i>Redox Biology</i> , 2015, 5, 422.	3.9	14
41	Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor. <i>Case Reports in Oncology</i> , 2015, 8, 461-465.	0.3	13
42	The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury. <i>Expert Review of Hematology</i> , 2017, 10, 575-582.	1.0	13
43	Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets. <i>Case Reports in Oncology</i> , 2016, 9, 285-289.	0.3	12
44	A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient after Priming with RRx-001. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10, CMO.S40429.	0.6	12
45	Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice. <i>Molecular Pharmaceutics</i> , 2019, 16, 2929-2934.	2.3	12
46	Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation. <i>Medical Oncology</i> , 2016, 33, 85.	1.2	11
47	Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 455-456.	0.6	11
48	Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5076-5082.	1.6	11
49	Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients. <i>Oxford Medical Case Reports</i> , 2019, 2019, 461-463.	0.2	11
50	NO or No NO, Increased Reduction of Nitrite to Nitric Oxide by Modified Red Blood Cells. <i>Blood</i> , 2011, 118, 2125-2125.	0.6	11
51	Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC. <i>Respiratory Medicine Case Reports</i> , 2016, 18, 62-65.	0.2	10
52	A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs). <i>Oncolmmunology</i> , 2018, 7, e1478648.	2.1	10
53	RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2045-2050.	1.2	10
54	Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19. <i>Seminars in Oncology</i> , 2020, 47, 305-308.	0.8	10

#	ARTICLE	IF	CITATIONS
55	RRx-001, a downregulator of the CD47- SIRP $\alpha$ checkpoint pathway, does not cause anemia or thrombocytopenia. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 355-357.	1.5	10
56	Abstract 4371: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors. Cancer Research, 2012, 72, 4371-4371.	0.4	10
57	Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors. Oncotarget, 2017, 8, 102511-102520.	0.8	10
58	Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. Oncotarget, 2016, 7, 40781-40791.	0.8	10
59	Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents. Biomolecules, 2016, 6, 32.	1.8	9
60	RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic". Oncoimmunology, 2020, 9, 1746172.	2.1	9
61	RRx-001 and the "Right stuff" Protection and treatment in outer space. Life Sciences in Space Research, 2022, 35, 69-75.	1.2	9
62	In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit. Translational Lung Cancer Research, 2021, 10, 274-278.	1.3	8
63	RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated Mice. Frontiers in Pharmacology, 2021, 12, 676396.	1.6	8
64	Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas. Journal of Drug Targeting, 2021, 29, 998-1003.	2.1	8
65	Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix. Expert Opinion on Drug Delivery, 2020, 17, 741-742.	2.4	7
66	Abstract 3515: RRx-001: A double action systemically non-toxic epigenetic agent for cancer therapy. , 2015, , .		7
67	RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor. Case Reports in Oncology, 2017, 10, 276-280.	0.3	6
68	A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets. European Urology, 2018, 73, 306-307.	0.9	6
69	Anti-Myeloma Activity of a Novel Free Radical Inducer Rx-001. Blood, 2014, 124, 4712-4712.	0.6	6
70	Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma. Expert Opinion on Investigational Drugs, 2021, 30, 177-183.	1.9	5
71	Abstract 1420: RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase. Cancer Research, 2014, 74, 1420-1420.	0.4	5
72	Phase I pilot study of RRx-001 + nivolumab in patients with traditionally non-checkpoint inhibitor-responsive cancers (PRIMETIME).. Journal of Clinical Oncology, 2020, 38, e151119-e151119.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy. <i>Oncotarget</i> , 2016, 7, 9041-9045.	0.8	5
74	A note on improved statistical approaches to account for pseudoprogression. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 621-626.	1.1	4
75	A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2018, 6, 232470961876008.	0.3	4
76	COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188412.	3.3	4
77	RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4713.	1.8	4
78	Abstract C181: RRx-001 combined with anti-PD-L1 antibody increases the complete response rate in a preclinical myeloma model. <i>Molecular Cancer Therapeutics</i> , 2015, 14, C181-C181.	1.9	4
79	Nitrite may serve as a combination partner and a biomarker for the anti-cancer activity of RRx-001. <i>Biorheology</i> , 2019, 56, 221-235.	1.2	3
80	A short discussion about the SARS-CoV-2 mRNA-1273 vaccine. <i>International Journal of Infectious Diseases</i> , 2021, 104, 532-533.	1.5	3
81	Abstract 2068: RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI In preclinical tumor models. <i>Cancer Research</i> , 2014, 74, 2068-2068.	0.4	3
82	Targeting Hyponitroxia in Cancer Therapy. , 2015, , 39-48.		2
83	Abstract 676: Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. <i>Cancer Research</i> , 2011, 71, 676-676.	0.4	2
84	Abstract 2165: Enhanced uptake and accumulation of temozolomide and irinotecan in orthotopically-implanted gliomas by vascular priming with RRx-001. <i>Cancer Research</i> , 2016, 76, 2165-2165.	0.4	2
85	RRx-001 Reset: Chemoresensitization via NO-Mediated M1 Macrophage Repolarization. , 2017, , 35-56.		1
86	Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule ofRRx-001(001) in reducing incidence, severity and duration of severe oral mucositis (SOM) inpatients receiving concomitant chemoradiation (CRT) for advanced head and neck cancer (HNC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 12081-12081.	0.8	1
87	Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 2478-2481.	0.2	0
88	Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-beta. <i>American Journal of Cancer Research</i> , 2021, 11, 5184-5189.	1.4	0
89	The small molecule NLRP3 inhibitor RRx-001 potentiates regorafenib activity and attenuates regorafenib-induced toxicity in mice bearing human colorectal cancer xenografts.. <i>American Journal of Cancer Research</i> , 2022, 12, 1912-1918.	1.4	0